semaglutide news today october 2025 Medicare will negotiate Novo's GLP-1 drug price. Here's what that means for Ozempic, Wegovy Semaglutide Market Size, Share &

What are the main side effects of using CJC 1295 and ipamorelin

Multiple studies (in vitro and in vivo) demonstrate the association between IGF-1 deficit and deregulated lipid metabolism, cardiovascular disease, diabetes, and an altered metabolic profile of diabetic patients

Yet, many myths surround who should be prescribed these drugs, how they work and what they can and cannot do

A case report and survey

RCT STEP 9 - Semaglutide vs Placebo for Knee Osteoarthritis in Patients with Obesity, NEJM (2024) [PubMed abstract] The STEP 9 study enrolled 407 patients with BMI 30 and a clinical and radiologic diagnosis of moderate knee osteoarthritis with at least moderate pain Main inclusion criteria Age 18 years or older BMI 30 ACR diagnostic criteria for knee OA Moderate X-ray changes (Kellgren-Lawrence grade 2 or 3) in target knee Knee OA WOMAC pain score of 40 Main exclusion criteria Use of opioid medications Use of obesity medication within 90 days Knee injection within 90 days Baseline characteristics Average age - 56 years Average weight - 239 lbs (108.6 kg) Average BMI - 40.3 Female sex - 82% Average WOMAC pain score - 70.9 Randomized treatment groups Group 1 (271 patients): Semaglutide 2.4 mg once weekly Group 2 (136 patients): Placebo Semaglutide was started at 0.24 mg once weekly and titrated over 16 weeks to 2.4 mg The percentage change in body weight and the change in the WOMAC pain score (scale 0 - 100, with higher scores meaning worse outcomes) from baseline to week 68 Primary outcome: Results Among participants with obesity and knee osteoarthritis with moderate-to-severe pain, treatment with once-weekly injectable semaglutide resulted in significantly greater reductions in body weight and pain related to knee osteoarthritis than placebo

Critical Certification Requirements To get into global markets, you need a wide range of certifications